Table 1.
Reference | Randomized participants | Geographic region* | Multicenter | Agent | Study design | Primary endpoint | Validated outcome measure? | Significant difference of primary endpoint? |
---|---|---|---|---|---|---|---|---|
Kaiser et al51 | 299 | Northern America | Yes | Topical fluticasone furoate | 15 days (during local allergy season), two arms: 1 10 mg versus placebo | Symptom score | No | Yes |
Patel et al44 | 320 | Northern America | No | Topical olopatadine | 1 day (allergen challenge chamber), four arms: once at 0.2%; 0.4%; or 0.6% versus placebo | Symptom score | Environmental exposure chamber was validated against natural exposure45,46 | Yes (0.6%) |
Patel and Patel47 | 403 | Northern America | No | Oral levocetirizine versus montelukast versus placebo | 2 days (allergen challenge chamber), three arms: levocetirizine 5 mg once daily versus montelukast 10 mg once daily versus placebo | Symptom score | No | Yes (levocetirizine) |
Day et al50 | 379 | Northern America | Yes | Oral loratadine and montelukast versus phenylephrine versus placebo | 2 days (allergen challenge chamber), three arms: loratadine 10 mg and montelukast 10 mg once daily versus phenylephrine 10 mg once daily versus placebo | Peak nasal flow | No | Yes (loratadine and montelukast) |
Moinuddin et al48 | 72 | Northern America | No | Oral fexofenadine and pseudoephedrine versus loratadine and montelukast | 2 weeks (during local allergy season), two arms: fexofenadine 60 mg and pseudoephedrine 120 mg twice daily versus loratadine, 10 mg and montelukast, 10 mg once daily | Not specifically designated | Rhinoconjunctivitis Quality of Life Questionnaire45 | Not applicable |
Note:
Geographical subregion as defined by the United Nations Organization.